{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:50:07Z","timestamp":1790394607525,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/cco.0b013e32833d58f2","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T04:16:04Z","timestamp":1280808964000},"page":"419-423","source":"Crossref","is-referenced-by-count":15,"title":["Mantle cell lymphoma in relapse: the role of emerging new drugs"],"prefix":"10.1097","volume":"22","author":[{"given":"Catherine SM","family":"Diefenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V78.2.259.bloodjournal782259","article-title":"bcl-1, t(11;14), and mantle cell-derived lymphomas","volume":"78","author":"Raffeld","year":"1991","journal-title":"Blood"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","article-title":"Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene","volume":"13","author":"Bodrug","year":"1994","journal-title":"EMBO J"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood.V100.8.2950","article-title":"Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index","volume":"100","author":"Lim","year":"2002","journal-title":"Blood"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A","volume":"265","author":"Yoshida","year":"1990","journal-title":"J Biol Chem"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2009.19","article-title":"Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy","volume":"23","author":"Wang","year":"2009","journal-title":"Leukemia"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.leukres.2006.03.004","article-title":"Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment","volume":"30","author":"Venkataraman","year":"2006","journal-title":"Leuk Res"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.4049\/jimmunol.166.5.3130","article-title":"Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells","volume":"166","author":"Marshansky","year":"2001","journal-title":"J Immunol"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/1042819031000151112","article-title":"Altered apoptosis pathways in mantle cell lymphoma","volume":"45","author":"Rummel","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2141.2009.07797.x","article-title":"The antihistaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor","volume":"146","author":"Paoluzzi","year":"2009","journal-title":"Br J Haematol"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"Am J Pathol"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3109\/10428190903207548","article-title":"Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies","volume":"50","author":"Coiffier","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1158\/0008-5472.CAN-09-1095","article-title":"MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas","volume":"69","author":"Navarro","year":"2009","journal-title":"Cancer Res"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32833d58f2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:11:08Z","timestamp":1620951068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201009000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32833d58f2","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}